Prediagnosis BMI Linked to CRC Mortality

Share this content:
Prediagnosis BMI Linked to CRC Mortality
Prediagnosis BMI Linked to CRC Mortality

(HealthDay News) — High prediagnosis body mass index (BMI) is associated with increased mortality after colorectal cancer diagnosis, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 9 in San Diego.

Peter T. Campbell, PhD, from the American Cancer Society in Atlanta, and colleagues used the Colon Cancer Family Registry (1997 to 2008) to identify a multicenter cohort of 6,763 patients with invasive colorectal cancer.

Mortality records and patient follow-up (median 5.3 years) were used to determine vital status. Self-reports of height and weight were used to assess BMI two years before diagnosis, BMI at age 20 years, and adult weight gain.

RELATED: Lifestyle Factors Before CRC Diagnosis May Affect Survival

The researchers found that 2,335 patients died during follow-up. There was a higher risk of all-cause mortality overall for those with higher BMI 2 years before cancer diagnosis (per 5-kg/m²; hazard ratio [HR], 1.10), with similar associations seen when stratified by gender (men: HR, 1.07; women: HR, 1.11).

Microsatellite instability (MSI) status (MS-stable/MSI-low: HR, 1.08; MSI-high: HR, 1.19) was also associated with higher risk of all-cause mortality. Risk of death was lower for those with MSI-high and normal BMI (HR, 0.77; 95% confidence interval [CI], 0.59 to 1.00), higher for MS-stable/MSI-low and high (≥30 kg/m²) BMI (HR, 1.23; 95% CI, 1.07 to 1.42), and similar for MSI-high and high BMI (HR, 0.97; 95% CI, 0.72 to 1.30), compared to those with MS-stable/MSI-low and normal BMI.

"[Our data] suggest that prediagnosis BMI may be something that clinicians should consider when managing patient care," Campbell said in a statement.


  1. Campbell PT, Newton C, Newcomb PA, et al. Abstract LB-276. Presented at: American Association for Cancer Research Annual Meeting 2014. April 5-9, 2014; San Diego.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs